What is DARE's market cap?

$12.88M, based on the Nov 2 close of $0.66.

Does Dare Bioscience pay a dividend?

No regular cash dividend has been paid in the last year.

How much of DARE is sold short?

1.1M shares, 6.2% of float, as of Oct 15, 2026.

What sector is DARE in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · DAREHealthcarePharmaceuticals

Dare Bioscience, Inc. Common Stock (DARE)

$0.6550−6.38%

Close Nov 2, 2026 · split-adjusted

Oct 30, 2026$0.70▼ 64.31% in range

Oct 31, 2025Low $0.64 · High $3.27Oct 30, 2026

What changed · written from our data

As of Nov 2, 2026

Dare Bioscience closed at $0.66 on Nov 2, down 6.38%, within 1.7% of its 52-week closing low. Volume of 206.4K shares was 1.49× its 20-day average (above normal).

Split-adjusted performance: -22.3% over one month, -78.9% over six months, -66.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $187.55K, with a net margin of -1590.4%.

Short interest was 1.1M shares at the Oct 15 settlement, up 24.0% from the prior report (6.2% of float, 10.3 days to cover).

Market cap$12.9M19.7M shares

Revenue · quarter$187.5K—

Diluted EPS$-0.20—

P/E · TTM—P/S 9.4×

Net margin-1,590.4%Gross -70.6%

Dividend yieldNone

52-week range0.64 – 3.27−80.0% from high

Volume206.4K1.49× 20-day avg

Volatility · 60d99.6%Annualised

Short % of float6.2%10.3 days to cover

Net cash$12.5MCash $12.6M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.7%1M −22.3%3M −51.1%6M −78.9%YTD −66.1%1Y −66.1%3Y −86.9%5Y −96.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum7

Revenue growth—

Net margin15

Value (low P/E)—

Size18

Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.

Short interest

Details →

Shares short1.1M+24.0% vs prior

Days to cover10.3Settled Oct 15

% of float6.2%

Short vol. 10d48.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
DAREDare Bioscience	$0.6550	−6.38%	−78.9%	—	−1590.4%	—	$12.9M
BFRIBiofrontera	$0.8701	−0.32%	−21.6%	+32.9%	−5.0%	—	$12.9M	Compare
HINDVyome Holdings	$1.76	−2.22%	−15.8%	—	−2543.3%	—	$12.4M	Compare
KTTAPasithea Therapeutics	$0.3680	−0.59%	−56.5%	—	—	—	$12.3M	Compare
LPCNLipocine	$1.45	+0.69%	−36.7%	−100.0%	—	—	$12.0M	Compare
BIVIBioVie	$1.37	−4.20%	−20.3%	—	—	—	$11.9M	Compare
CLRBCellectar Biosciences INC NEW	$1.22	+1.24%	−56.9%	—	—	—	$11.5M	Compare
BOLTBolt Biotherapeutics	$6.24	−5.31%	+23.3%	−99.7%	−154400.0%	—	$14.7M	Compare
RKTORocket One	$0.4493	−7.68%	—	—	—	—	$11.2M	Compare

News about Dare Bioscience

All news →

No recent articles focused on Dare Bioscience.

Quick answers

What does Dare Bioscience do?: Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health.
What is DARE's market cap?: $12.88M, based on the Nov 2 close of $0.66.
Does Dare Bioscience pay a dividend?: No regular cash dividend has been paid in the last year.
How much of DARE is sold short?: 1.1M shares, 6.2% of float, as of Oct 15, 2026.
What sector is DARE in?: Healthcare, in the Pharmaceuticals industry.

About Dare Bioscience

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

HQ: San Diego, CA24 employeesListed Apr 10, 2014darebioscience.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology